Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2015, Article ID 484231, 7 pages
http://dx.doi.org/10.1155/2015/484231
Research Article

Four-Point Preprandial Self-Monitoring of Blood Glucose for the Assessment of Glycemic Control and Variability in Patients with Type 2 Diabetes Treated with Insulin and Vildagliptin

1CNR Institute of Neuroscience, Corso Stati Uniti 4, 35127 Padova, Italy
2Department of Clinical Sciences, Lund University, B11 BMC, 22184 Lund, Sweden
3Novartis Pharma AG, 4002 Basel, Switzerland
4Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, NJ 07936, USA

Received 5 May 2015; Revised 2 October 2015; Accepted 5 October 2015

Academic Editor: Michael Horowitz

Copyright © 2015 Andrea Tura et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. Ahrén, “Insulin plus incretin: a glucose-lowering strategy for type 2-diabetes,” World Journal of Diabetes, vol. 5, no. 1, pp. 40–51, 2014. View at Publisher · View at Google Scholar
  2. A. Schweizer, J. E. Foley, W. Kothny, and B. Ahrén, “Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin,” Vascular Health and Risk Management, vol. 9, no. 1, pp. 57–64, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. W. Kothny, J. Foley, P. Kozlovski, Q. Shao, B. Gallwitz, and V. Lukashevich, “Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus,” Diabetes, Obesity and Metabolism, vol. 15, no. 3, pp. 252–257, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. V. Fonseca, A. Schweizer, D. Albrecht, M. A. Baron, I. Chang, and S. Dejager, “Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes,” Diabetologia, vol. 50, no. 6, pp. 1148–1155, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. T. Vilsbøll, J. Rosenstock, H. Yki-Järvinen et al., “Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes,” Diabetes, Obesity and Metabolism, vol. 12, no. 2, pp. 167–177, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. A. H. Barnett, B. Charbonnel, M. Donovan, D. Fleming, and R. Chen, “Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin,” Current Medical Research and Opinion, vol. 28, no. 4, pp. 513–523, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Kishimoto and M. Noda, “Effect of the addition of sitagliptin and miglitol on insulin-treated type 2 diabetes,” Diabetes Therapy, vol. 3, article 11, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. H. Yki-Järvinen, J. Rosenstock, S. Durán-Garcia et al., “Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥ 52-week randomized, double-blind study,” Diabetes Care, vol. 36, no. 12, pp. 3875–3881, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. S. E. Siegelaar, F. Holleman, J. B. L. Hoekstra, and J. H. DeVries, “Glucose variability; does it matter?” Endocrine Reviews, vol. 31, no. 2, pp. 171–182, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. E. S. Kilpatrick, “Arguments for and against the role of glucose variability in the development of diabetes complications,” Journal of Diabetes Science and Technology, vol. 3, no. 4, pp. 649–655, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Ceriello, “The glucose triad and its role in comprehensive glycaemic control: current status, future management,” International Journal of Clinical Practice, vol. 64, no. 12, pp. 1705–1711, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. L. Monnier, C. Colette, and D. Owens, “The glycemic triumvirate and diabetic complications: is the whole greater than the sum of its component parts?” Diabetes Research and Clinical Practice, vol. 95, no. 3, pp. 303–311, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. R. Marfella, M. Barbieri, R. Grella, M. R. Rizzo, G. F. Nicoletti, and G. Paolisso, “Effects of vildagliptin twice daily vs. sitagliptin once daily on 24-hour acute glucose fluctuations,” Journal of Diabetes and Its Complications, vol. 24, no. 2, pp. 79–83, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. B. Guerci, L. Monnier, P. Serusclat et al., “Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study,” Diabetes & Metabolism, vol. 38, no. 4, pp. 359–366, 2012. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Sakamoto, R. Nishimura, T. Irako, D. Tsujino, K. Ando, and K. Utsunomiya, “Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study),” Cardiovascular Diabetology, vol. 11, article 92, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. L. He, G. Foteinos, S. Neelakantham et al., “Differential effects of vildagliptin and glimepiride on glucose fluctuations in patients with type 2 diabetes mellitus assessed using continuous glucose monitoring,” Diabetes, Obesity and Metabolism, vol. 15, no. 12, pp. 1111–1119, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. K. Yoshioka, H. Isotani, S.-I. Ohashi, and M. Imamura, “Efficacy of vildagliptin on glucose fluctuation in Japanese type 2 diabetic patients with ongoing sulfonylurea based oral glycemic agent therapy,” Diabetes and Metabolic Syndrome, vol. 7, no. 1, pp. 32–34, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. Y. Mori, Y. Taniguchi, K. Matsuura, K. Sezaki, J. Yokoyama, and K. Utsunomiya, “Effects of sitagliptin on 24-H glycemic changes in japanese patients with type 2 diabetes assessed using continuous glucose monitoring,” Diabetes Technology & Therapeutics, vol. 13, no. 7, pp. 699–703, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. Y. Mori, Y. Taniguchi, S. Miyazaki, J. Yokoyama, and K. Utsunomiya, “Effects of add-on treatment with sitagliptin on narrowing the range of glucose fluctuations in Japanese type 2 diabetes patients receiving insulin therapy,” Diabetes Technology & Therapeutics, vol. 15, no. 3, pp. 237–240, 2013. View at Publisher · View at Google Scholar
  20. S. Shimoda, S. Iwashita, S. Ichimori et al., “Efficacy and safety of sitagliptin as add-on therapy on glycemic control and blood glucose fluctuation in Japanese type 2 diabetes subjects ongoing with multiple daily insulin injections therapy,” Endocrine Journal, vol. 60, no. 10, pp. 1207–1214, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Farngren, M. Persson, A. Schweizer, J. E. Foley, and B. Ahrén, “Glucagon dynamics during hypoglycemia and food-re-challenge in insulin-treated patients with type 2 diabetes in the presence and absence of the DPP-4 inhibitor vildagliptin,” Diabetes, Obesity and Metabolism, vol. 16, no. 9, pp. 812–818, 2014. View at Publisher · View at Google Scholar
  22. D. Rodbard, “Clinical interpretation of indices of quality of glycemic control and glycemic variability,” Postgraduate Medicine, vol. 123, no. 4, pp. 107–118, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. D. Rodbard, “Interpretation of continuous glucose monitoring data: glycemic variability and quality of glycemic control,” Diabetes Technology & Therapeutics, vol. 11, supplement 1, pp. S55–S67, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. N. R. Hill, P. C. Hindmarsh, R. J. Stevens, I. M. Stratton, J. C. Levy, and D. R. Matthews, “A method for assessing quality of control from glucose profiles,” Diabetic Medicine, vol. 24, no. 7, pp. 753–758, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Schlichtkrull, O. Munck, and M. Jersild, “The M-value, an index of blood-sugar control in diabetics,” Acta Medica Scandinavica, vol. 177, pp. 95–102, 1965. View at Google Scholar · View at Scopus
  26. B. P. Kovatchev, D. J. Cox, L. A. Gonder-Frederick, and W. Clarke, “Symmetrization of the blood glucose measurement scale and its applications,” Diabetes Care, vol. 20, no. 11, pp. 1655–1658, 1997. View at Publisher · View at Google Scholar · View at Scopus
  27. B. P. Kovatchev, E. Otto, D. Cox, L. Gonder-Frederick, and W. Clarke, “Evaluation of a new measure of blood glucose variability in diabetes,” Diabetes Care, vol. 29, no. 11, pp. 2433–2438, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. D. Rodbard, “New and improved methods to characterize glycemic variability using continuous glucose monitoring,” Diabetes Technology & Therapeutics, vol. 11, no. 9, pp. 551–565, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. F. J. Service, G. D. Molnar, J. W. Rosevear, E. Ackerman, L. C. Gatewood, and W. F. Taylor, “Mean amplitude of glycemic excursions, a measure of diabetic instability,” Diabetes, vol. 19, no. 9, pp. 644–655, 1970. View at Publisher · View at Google Scholar · View at Scopus
  30. A. N. Pitsillides, S. M. Anderson, and B. Kovatchev, “Hypoglycemia risk and glucose variability indices derived from routine self-monitoring of blood glucose are related to laboratory measures of insulin sensitivity and epinephrine counterregulation,” Diabetes Technology & Therapeutics, vol. 13, no. 1, pp. 11–17, 2011. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Bragd, U. Adamson, L. B. Bäcklund, P. E. Lins, E. Moberg, and P. Oskarsson, “Can glycaemic variability, as calculated from blood glucose self-monitoring, predict the development of complications in type 1 diabetes over a decade?” Diabetes & Metabolism, vol. 34, no. 6, pp. 612–616, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. S. A. P. Chubb, K. Van Minnen, W. A. Davis, D. G. Bruce, and T. M. E. Davis, “The relationship between self-monitoring of blood glucose results and glycated haemoglobin in type 2 diabetes: the Fremantle Diabetes study,” Diabetes Research and Clinical Practice, vol. 94, no. 3, pp. 371–376, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. J. C. Kuenen, R. Borg, D. J. Kuik et al., “Does glucose variability influence the relationship between mean plasma glucose and HbA1c levels in type 1 and type 2 diabetic patients?” Diabetes Care, vol. 34, no. 8, pp. 1843–1847, 2011. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Muggeo, G. Zoppini, E. Bonora et al., “Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes study,” Diabetes Care, vol. 23, no. 1, pp. 45–50, 2000. View at Publisher · View at Google Scholar · View at Scopus
  35. T. Haak, A. Tiengo, E. Draeger, M. Suntum, and W. Waldhäusl, “Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes,” Diabetes, Obesity and Metabolism, vol. 7, no. 1, pp. 56–64, 2005. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Hanefeld, C. Koehler, C. Hoffmann, K. Wilhelm, W. Kamke, and H. Gerstein, “Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early Type 2 diabetes,” Diabetic Medicine, vol. 27, no. 2, pp. 175–180, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. T. Takao, T. Ide, H. Yanagisawa, M. Kikuchi, S. Kawazu, and Y. Matsuyama, “The effects of fasting plasma glucose variability and time-dependent glycemic control on the long-term risk of retinopathy in type 2 diabetic patients,” Diabetes Research and Clinical Practice, vol. 91, no. 2, pp. e40–e42, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. N. R. Hill, A. Tsapas, P. Hindmarsh, and D. R. Matthews, “Methodology for quantifying fasting glucose homeostasis in type 2 diabetes: observed variability and lability,” Journal of Diabetes Science and Technology, vol. 7, no. 3, pp. 640–645, 2013. View at Publisher · View at Google Scholar · View at Scopus